{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:34:35Z","timestamp":1777419275656,"version":"3.51.4"},"reference-count":72,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Parasitology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.pt.2018.08.006","type":"journal-article","created":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T08:23:05Z","timestamp":1535790185000},"page":"818-827","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["The Long Wait for a New Drug for Human African Trypanosomiasis"],"prefix":"10.1016","volume":"34","author":[{"given":"Catriona H.","family":"Baker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan C.","family":"Welburn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pt.2018.08.006_bib0005","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1471-4922(00)01839-0","article-title":"Sleeping sickness \u2013 a tale of two diseases","volume":"17","author":"Welburn","year":"2001","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.pt.2018.08.006_bib0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001541","article-title":"Human African trypanosomiasis in South Sudan: how can we prevent a new epidemic?","volume":"6","author":"Ruiz-Postigo","year":"2012","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2018.08.006_bib0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001859","article-title":"Estimating and mapping the population at risk of sleeping sickness","volume":"6","author":"Simarro","year":"2012","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2018.08.006_bib0020","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cmi.2015.04.011","article-title":"The neglected zoonoses \u2013 the case for integrated control and advocacy","volume":"21","author":"Welburn","year":"2015","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.pt.2018.08.006_bib0025","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/j.1365-3156.2005.01470.x","article-title":"Quantifying the level of under-reporting of sleeping sickness cases","volume":"10","author":"Odiit","year":"2005","journal-title":"Trop. Med. Int. Health"},{"key":"10.1016\/j.pt.2018.08.006_bib0030","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1098\/rstb.2009.0067","article-title":"Neglected and endemic zoonoses","volume":"364","author":"Maudlin","year":"2009","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.pt.2018.08.006_bib0035","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1752-1505-5-7","article-title":"Challenges of controlling sleeping sickness in areas of violent conflict: experience in the Democratic Republic of Congo","volume":"5","author":"Tong","year":"2011","journal-title":"Confl. Health"},{"key":"10.1016\/j.pt.2018.08.006_bib0040","series-title":"Sustaining the Drive to Overcome the Global Impact of Neglected Tropical Diseases: Second WHO Report on Neglected Tropical Diseases","author":"WHO","year":"2013"},{"key":"10.1016\/j.pt.2018.08.006_bib0045","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.pt.2006.01.011","article-title":"Crisis, what crisis? Control of Rhodesian sleeping sickness","volume":"22","author":"Welburn","year":"2006","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.pt.2018.08.006_bib0050","series-title":"One Health: The Theory and Practice of Integrated Health Approaches","first-page":"201","article-title":"Human and animal African trypanosomiasis","author":"Welburn","year":"2015"},{"key":"10.1016\/j.pt.2018.08.006_bib0055","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.pt.2015.11.008","article-title":"Beyond tsetse \u2013 implications for research and control of human African trypanosomiasis epidemics","volume":"32","author":"Welburn","year":"2016","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.pt.2018.08.006_bib0060","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.actatropica.2016.08.022","article-title":"Impact of mass chemotherapy in domestic livestock to control zoonotic T. b. rhodesiense","volume":"165","author":"Fyfe","year":"2016","journal-title":"Acta Trop."},{"key":"10.1016\/j.pt.2018.08.006_bib0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001211","article-title":"Characterisation of the wildlife reservoir community for human and animal trypanosomiasis in the Luangwa Valley, Zambia","volume":"5","author":"Anderson","year":"2011","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2018.08.006_bib0070","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.mib.2007.09.014","article-title":"The cell biology of Trypanosoma brucei differentiation","volume":"10","author":"Fenn","year":"2007","journal-title":"Curr. Opin. Microbiol."},{"key":"10.1016\/j.pt.2018.08.006_bib0075","article-title":"The unknown risk of vertical transmission in sleeping sickness \u2013 a literature review","volume":"4","author":"Linder","year":"2010","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2018.08.006_bib0080","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S0140-6736(03)15345-7","article-title":"Possible cases of sexual and congenital transmission of sleeping sickness","volume":"363","author":"Rocha","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.pt.2018.08.006_bib0085","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1136\/bmj.325.7357.203","article-title":"Human African trypanosomiasis","volume":"325","author":"Stich","year":"2002","journal-title":"Br. Med. J."},{"key":"10.1016\/j.pt.2018.08.006_bib0090","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1756-3305-1-3","article-title":"The history of African trypanosomiasis","volume":"1","author":"Steverding","year":"2008","journal-title":"Parasit. Vectors"},{"key":"10.1016\/j.pt.2018.08.006_bib0095","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1179\/2047773213Y.0000000105","article-title":"A current analysis of chemotherapy strategies for the treatment of human African trypanosomiasis","volume":"107","author":"Babokhov","year":"2013","journal-title":"Pathog. Glob. Health"},{"key":"10.1016\/j.pt.2018.08.006_bib0100","doi-asserted-by":"crossref","first-page":"70","DOI":"10.7861\/clinmedicine.15-1-70","article-title":"Human African trypanosomiasis in non-endemic countries","volume":"15","author":"Sudarshi","year":"2015","journal-title":"Clin. Med."},{"key":"10.1016\/j.pt.2018.08.006_bib0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0118370","article-title":"Clinical profiles, disease outcome and comorbidities among T. b. rhodesiense sleeping sickness patients in Uganda","volume":"10","author":"Kato","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.pt.2018.08.006_bib0110","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.pt.2011.04.005","article-title":"New techniques for old diseases I. Diagnostics for human sleeping sickness \u2013 sense and sensitivity","volume":"27","author":"Wastling","year":"2011","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.pt.2018.08.006_bib0115","first-page":"1","article-title":"Latent Trypanosoma brucei gambiense foci in Uganda: a silent epidemic in children and adults?","volume":"18","author":"Wastling","year":"2011","journal-title":"Parasitology"},{"key":"10.1016\/j.pt.2018.08.006_bib0120","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1016\/S0140-6736(01)07096-9","article-title":"Identification of human infective trypanosomes in animal reservoir of sleeping sickness in Uganda by means of serum-resistance-associated (SRA) gene","volume":"358","author":"Welburn","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.pt.2018.08.006_bib0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003373","article-title":"Evaluation of the diagnostic accuracy of prototype rapid tests for human African trypanosomiasis","volume":"8","author":"Sternberg","year":"2014","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2018.08.006_bib0130","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S1473-3099(13)70191-9","article-title":"Do we need new drugs against human African trypanosomiasis?","volume":"13","author":"Stich","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.pt.2018.08.006_bib0135","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1756-3305-3-15","article-title":"The development of drugs for treatment of sleeping sickness: a historical review","volume":"3","author":"Steverding","year":"2010","journal-title":"Parasit. Vectors"},{"key":"10.1016\/j.pt.2018.08.006_bib0140","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.bbamcr.2006.08.019","article-title":"Metabolic functions of glycosomes in trypanosomatids","volume":"1763","author":"Michels","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.pt.2018.08.006_bib0145","series-title":"Desk Reference of Clinical Pharmacology","author":"Ebadi","year":"2007"},{"key":"10.1016\/j.pt.2018.08.006_bib0150","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1093\/nar\/gkf394","article-title":"Pentamidine inhibits catalytic activity of group I intron Ca.LSU by altering RNA folding","volume":"30","author":"Zhang","year":"2002","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.pt.2018.08.006_bib0155","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/jac\/dkt442","article-title":"Trypanosoma brucei aquaglyceroporin 2 is a high-affinity transporter for pentamidine and melaminophenyl arsenic drugs and the main genetic determinant of resistance to these drugs","volume":"69","author":"Munday","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.pt.2018.08.006_bib0160","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.pt.2012.12.005","article-title":"Drug resistance in African trypanosomiasis: the melarsoprol and pentamidine story","volume":"29","author":"Baker","year":"2013","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.pt.2018.08.006_bib0165","series-title":"WHO Model Prescribing Information: Drugs Used in Parasitic Diseases","author":"WHO","year":"1995"},{"key":"10.1016\/j.pt.2018.08.006_bib0170","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1586\/14787210.2014.959496","article-title":"Treatment options for second-stage gambiense human African trypanosomiasis","volume":"12","author":"Eperon","year":"2014","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"10.1016\/j.pt.2018.08.006_bib0175","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.pt.2003.09.002","article-title":"Chemotherapy of human African trypanosomiasis: current and future prospects","volume":"19","author":"Fairlamb","year":"2003","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.pt.2018.08.006_bib0180","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0140-6736(04)16940-7","article-title":"Efficacy of 10-day melarsoprol schedule 2 years after treatment for late-stage gambiense sleeping sickness","volume":"364","author":"Schmid","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.pt.2018.08.006_bib0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002910","article-title":"The death and life of the resurrection drug","volume":"8","author":"Ebikeme","year":"2014","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2018.08.006_bib0190","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1371\/journal.pctr.0010039","article-title":"Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda","volume":"1","author":"Priotto","year":"2006","journal-title":"PLoS Clin. Trials"},{"key":"10.1016\/j.pt.2018.08.006_bib0195","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1086\/522982","article-title":"Nifurtimox\u2013eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo","volume":"45","author":"Priotto","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.pt.2018.08.006_bib0200","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(09)61117-X","article-title":"Nifurtimox\u2013eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial","volume":"374","author":"Priotto","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.pt.2018.08.006_bib0205","series-title":"Hunter\u2019s Tropical Medicine and Emerging Infectious Disease","first-page":"718","article-title":"African trypanosomiasis","author":"Krishna","year":"2013"},{"key":"10.1016\/j.pt.2018.08.006_bib0210","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1046\/j.1365-3156.2001.00775.x","article-title":"The phenomenon of treatment failures in human African trypanosomiasis","volume":"6","author":"Brun","year":"2001","journal-title":"Trop. Med. Int. Health"},{"key":"10.1016\/j.pt.2018.08.006_bib0215","doi-asserted-by":"crossref","first-page":"5602","DOI":"10.1128\/AAC.00246-11","article-title":"Anti-trypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness","volume":"55","author":"Kaiser","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2018.08.006_bib0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001308","article-title":"Melarsoprol cyclodextrin inclusion complexes as promising oral candidates for the treatment of human African trypanosomiasis","volume":"5","author":"Rodgers","year":"2011","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2018.08.006_bib0225","doi-asserted-by":"crossref","first-page":"783","DOI":"10.2471\/BLT.06.031955","article-title":"Melarsoprol versus eflornithine for treating late-stage Gambian trypanosomiasis in the Republic of Congo","volume":"84","author":"Balasegaram","year":"2006","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.pt.2018.08.006_bib0230","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1017\/S0031182012000169","article-title":"Update on field use of the available drugs for the chemotherapy of human African trypanosomiasis","volume":"139","author":"Simarro","year":"2012","journal-title":"Parasitology"},{"key":"10.1016\/j.pt.2018.08.006_bib0235","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3201\/eid1106.050036","article-title":"Trypanosomiasis relapse after melarsoprol therapy, Democratic Republic of Congo, 1982\u20132001","volume":"11","author":"P\u00e9pin","year":"2005","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.pt.2018.08.006_bib0240","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0167-6296(02)00126-1","article-title":"The price of innovation: new estimates of drug development costs","volume":"22","author":"DiMasi","year":"2003","journal-title":"J. Health Econ."},{"key":"10.1016\/j.pt.2018.08.006_bib0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000411","article-title":"Registering new drugs for low-income countries: the African challenge","volume":"8","author":"Moran","year":"2011","journal-title":"PLoS Med."},{"key":"10.1016\/j.pt.2018.08.006_bib0250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001734","article-title":"Pharmacology of DB844, an orally active aza analogue of pafuramidine, in a monkey model of second stage human African trypanosomiasis","volume":"6","author":"Thuita","year":"2012","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2018.08.006_bib0255","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1128\/AAC.00225-09","article-title":"New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289","volume":"53","author":"Wenzler","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2018.08.006_bib0260","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003409","article-title":"Chemotherapy of second stage human African trypanosomiasis: comparison between the parenteral diamidine DB829 and its oral prodrug DB868 in vervet Monkeys","volume":"9","author":"Thuita","year":"2015","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2018.08.006_bib0265","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1046\/j.1365-3156.2001.00803.x","article-title":"Drugs for neglected diseases: a failure of the market and a public health failure?","volume":"6","author":"Trouiller","year":"2001","journal-title":"Trop. Med. Int. Health"},{"key":"10.1016\/j.pt.2018.08.006_bib0270","first-page":"245","article-title":"Financing sustainable drug development for neglected diseases: a case of push-pull mechanisms and global public goods","volume":"45","author":"Le","year":"2014","journal-title":"Econ. Soc. Rev."},{"key":"10.1016\/j.pt.2018.08.006_bib0275","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.4155\/fmc.11.102","article-title":"Drugs for neglected diseases initiative model of drug development for neglected diseases: current status and future challenges","volume":"3","author":"Ioset","year":"2011","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.pt.2018.08.006_bib0280","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0140-6736(17)32758-7","article-title":"Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial","volume":"391","author":"Mesu","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.pt.2018.08.006_bib0285","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0140-6736(18)30019-9","article-title":"Oral fexinidazole for human African trypanosomiasis","volume":"391","author":"Chappuis","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.pt.2018.08.006_bib0290","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/infdis\/jir857","article-title":"Pharmacological validation of Trypanosoma brucei phosphodiesterases as novel drug targets","volume":"206","author":"De Koning","year":"2012","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.pt.2018.08.006_bib0295","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1021\/cb300326z","article-title":"Chemical proteomic analysis reveals the druggability of the kinome of Trypanosoma brucei","volume":"7","author":"Urbaniak","year":"2012","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.pt.2018.08.006_bib0300","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrmicro.2016.193","article-title":"Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need","volume":"15","author":"Field","year":"2017","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.pt.2018.08.006_bib0305","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1101\/gr.115089.110","article-title":"High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome","volume":"21","author":"Alsford","year":"2011","journal-title":"Genome Res."},{"key":"10.1016\/j.pt.2018.08.006_bib0310","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1017\/S0031182013001017","article-title":"Target-based drug discovery for human African trypanosomiasis: selection of molecular target and chemical matter","volume":"141","author":"Gilbert","year":"2013","journal-title":"Parasitology"},{"key":"10.1016\/j.pt.2018.08.006_bib0315","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1002\/cmdc.201500301","article-title":"Development of small-molecule Trypanosoma brucei N-myristoyltransferase inhibitors: discovery and optimisation of a novel binding mode","volume":"10","author":"Spinks","year":"2015","journal-title":"ChemMedChem"},{"key":"10.1016\/j.pt.2018.08.006_bib0320","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.pt.2007.08.019","article-title":"Target assessment for antiparasitic drug discovery","volume":"23","author":"Frearson","year":"2007","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.pt.2018.08.006_bib0325","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000923","article-title":"Fexinidazole \u2013 a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness","volume":"4","author":"Torreele","year":"2010","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2018.08.006_bib0330","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.exppara.2011.02.018","article-title":"Trypanosoma brucei gambiense: HMI-9 medium containing methylcellulose and human serum supports the continuous axenic in vitro propagation of the bloodstream form","volume":"128","author":"Van Reet","year":"2011","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.pt.2018.08.006_bib0335","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0169-4758(95)80046-8","article-title":"The 1901 Uganda sleeping sickness epidemic revised: a case of mistaken identity?","volume":"11","author":"Koerner","year":"1995","journal-title":"Parasitol. Today"},{"key":"10.1016\/j.pt.2018.08.006_bib0340","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.socscimed.2010.06.006","article-title":"Conflict and human African trypanosomiasis","volume":"72","author":"Berrang-Ford","year":"2011","journal-title":"Soc. Sci. Med."},{"key":"10.1016\/j.pt.2018.08.006_bib0345","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/1756-3305-6-281","article-title":"Cattle movements and trypanosomes: restocking efforts and the spread of Rhodesian sleeping sickness in post-conflict Uganda","volume":"6","author":"Selby","year":"2013","journal-title":"Parasit. Vectors"},{"key":"10.1016\/j.pt.2018.08.006_bib0350","doi-asserted-by":"crossref","first-page":"i53","DOI":"10.1093\/inthealth\/ihv071","article-title":"Social stigma towards neglected tropical diseases: a systematic review","volume":"8","author":"Hofstraat","year":"2016","journal-title":"Int. Health"},{"key":"10.1016\/j.pt.2018.08.006_bib0355","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.11473","article-title":"Population genomics reveals the origin and asexual evolution of human infective trypanosomes","volume":"5","author":"Weir","year":"2016","journal-title":"eLife"},{"key":"10.1016\/j.pt.2018.08.006_bib0360","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005000","article-title":"Novel financing model for neglected tropical diseases \u2013 Development Impact Bonds applied to sleeping sickness and rabies control","volume":"10","author":"Welburn","year":"2016","journal-title":"PLoS Negl. Trop. Dis."}],"container-title":["Trends in Parasitology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471492218301715?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471492218301715?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T07:33:28Z","timestamp":1761464008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471492218301715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":72,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S1471492218301715"],"URL":"https:\/\/doi.org\/10.1016\/j.pt.2018.08.006","relation":{},"ISSN":["1471-4922"],"issn-type":[{"value":"1471-4922","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Long Wait for a New Drug for Human African Trypanosomiasis","name":"articletitle","label":"Article Title"},{"value":"Trends in Parasitology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pt.2018.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}